Tesaro Inc. is moving forward with ambitions to expand the poly ADP-ribose polymerase (PARP) inhibitor Zejula (niraparib) to more indications beyond recurrent ovarian cancer, including as a front-line treatment for ovarian cancer, in combination with the immunotherapy Keytruda (pembrolizumab), in triple-negative breast cancer and lung cancer.
Management outlined the expansion strategy and some encouraging early data during an investor briefing at the American Society of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?